金属蛋白酶组织抑制剂-2联合胰岛素样生长因子结合蛋白7对脓毒症相关性急性肾损伤的临床应用价值研究进展  

Advances in the clinical value of tissue inhibitors of metalloproteinase-2 and insulin-like growth factor binding protein 7 in sepsis associated-acute kidney injury

作　　者：蒋伟 郑瑞强 Jiang Wei;Zheng Ruiqiang(Clinical Medical College,Yangzhou University,Department of Intensive Care Unit,Northern Jiangsu People's Hospital,Yangzhou 225001,Jiangsu,China)

机构地区：[1]扬州大学临床医学院,江苏省苏北人民医院重症医学科,江苏扬州225001

出　　处：《中华危重病急救医学》2022年第1期105-109,共5页Chinese Critical Care Medicine

基　　金：江苏省科技项目(BE2017691);江苏省扬州市"333工程"科研项目(BRA2020183)。

摘　　要：脓毒症是引起急性肾损伤(AKI)的重要原因,约60%的脓毒症患者会发生AKI。目前临床诊断AKI的标准仍然是基于血肌酐和尿量的变化,由于其在时间上存在滞后性,因此可能导致治疗时机延误,增加病死率。寻找一种类似"肌钙蛋白样"的诊断AKI的新型生物标志物,实现AKI的早期诊断和早期预防干预,对降低AKI的病死率具有重要意义。近些年研究表明,金属蛋白酶组织抑制剂-2(TIMP-2)和胰岛素样生长因子结合蛋白7(IGFBP7)可用于早期诊断脓毒症相关性急性肾损伤(SA-AKI),并且在SA-AKI的风险分层、预后判断及介入干预等方面亦有重要价值。现对TIMP-2和IGFBP7在SA-AKI中的应用研究进展进行综述。Sepsis is an important cause of acute kidney injury(AKI).About 60%of sepsis patients will develop AKI.At present,the standard of clinical diagnosis of AKI is still based on the changes in serum creatinine and urine volume.Because of its lag in time,it may lead to delay in treatment and increase the mortality.To find a new biomarker similar to"troponin"for the diagnosis of AKI,and to achieve the early diagnosis and prevention of AKI,is of great significance to reduce the mortality of AKI.In recent years,it has been found that tissue inhibitors of metalloproteinase-2(TIMP-2)and insulin-like growth factor-binding protein 7(IGFBP7)can be used for early diagnosis of sepsis associated-acute kidney injury(SA-AKI).They also have important values in risk stratification,prognosis judgment,intervention and other aspects of SA-AKI.In this paper,the research progress of the application of TIMP-2 and IGFBP7 in SA-AKI is reviewed.

关 键 词：金属蛋白酶组织抑制剂-2 胰岛素样生长因子结合蛋白7 细胞周期抑制蛋白阻滞剂 急性肾损伤 脓毒症 

分 类 号：R459.7[医药卫生—急诊医学] R692[医药卫生—治疗学]